Zhimei Song
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhimei Song has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Runliang Feng
School of Biological Science and Technology, University of Jinan, No. 336 West Road of Nanxinzhuang, Jinan 250022, Shandong Province, PR China
5 shared publicationsLi Zhu
School of Biological Science and Technology, University of Jinan, No. 336 West Road of Nanxinzhuang, Jinan 250022, Shandong Province, PR China
4 shared publicationsFangfang Teng
Guangrao People's Hospital, No. 180 Huayuan road, Guangrao county, Dongying 257300, Shandong Province, PR China
3 shared publicationsHongmei Xu
Department of Pharmaceutical Engineering, School of Biological Science and Technology, University of Jinan, No. 336 West Road of Nanxinzhuang, Jinan 250022, Shandong Province, PR China
3 shared publications- Runliang Feng
School of Biological Science and Technology, University of Jinan, No. 336 West Road of Nanxinzhuang, Jinan, 250022, Shandong Province, P. R. China
3 shared publications Shiyu Chen
School of Biological Science and Technology, University of Jinan, No. 336 West Road of Nanxinzhuang, Jinan 250022, Shandong Province, PR China
3 shared publications
Latest Publications
- 12 May 2022
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 216, 112559
Phenylboronic acid-modified polymaleic anhydride-F127 micelles for pH-activated targeting delivery of doxorubicin
- 12 May 2022
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 216, 112559
Phenylboronic acid-modified polymaleic anhydride-F127 micelles for pH-activated targeting delivery of doxorubicin
- 1 September 2020
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 587, 119626
Paclitaxel skin delivery by micelles-embedded Carbopol 940 hydrogel for local therapy of melanoma
- 1 September 2020
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 587, 119626
Paclitaxel skin delivery by micelles-embedded Carbopol 940 hydrogel for local therapy of melanoma
- 24 June 2020
- Published by Wiley in Journal of Biomedical Materials Research Part B: Applied Biomaterials
- Vol. 108 (8) , 3345-3355
Phenylboronic acid‐functionalized F127‐oligochitosan conjugate micelles for doxorubicin encapsulation
Doxorubicin shows good anticancer activity, but poor pharmacokinetic property and high organ toxicity restrict its clinical application. The synthesized phenylboronic acid‐modified F127‐chitosan conjugate was used to prepare doxorubicin‐loaded micelles through dialysis method. The physicochemical properties of the doxorubicin‐loaded micelles were characterized. These micelles were further evaluated for in vitro release/cytotoxicity, in vivo activity/biosafety, and pharmacokinetic studies. in vitro release experiment demonstrated that the release of doxorubicin from drug‐loaded micelles was pH‐dependent. in vitro cytotoxic study showed that the introduction of phenylboronic acid resulted in lower IC50 against B16 cells than that in non‐modified F127‐chitosan micelles group, and the doxorubicin‐loaded micelles displayed lower in vitro activity against B16, A549, and HT‐29 cells than free doxorubicin did. However, in vivo experiments confirmed that the doxorubicin‐loaded micelles were safe for mouse main organs, obviously improved pharmacokinetic parameters of doxorubicin in rat and achieved comparable inhibition of tumor growth with no animal death in B16‐bearing mice models throughout the experiment when compared with free doxorubicin. The phenylboronic acid‐sialic acid interaction and pH‐sensitive drug release might play important roles in increased tumor targeting and therapeutic effect of the doxorubicin‐loaded micelles.
- 24 June 2020
- Published by Wiley in Journal of Biomedical Materials Research Part B: Applied Biomaterials
- Vol. 108 (8) , 3345-3355
Phenylboronic acid‐functionalized F127‐oligochitosan conjugate micelles for doxorubicin encapsulation
Doxorubicin shows good anticancer activity, but poor pharmacokinetic property and high organ toxicity restrict its clinical application. The synthesized phenylboronic acid‐modified F127‐chitosan conjugate was used to prepare doxorubicin‐loaded micelles through dialysis method. The physicochemical properties of the doxorubicin‐loaded micelles were characterized. These micelles were further evaluated for in vitro release/cytotoxicity, in vivo activity/biosafety, and pharmacokinetic studies. in vitro release experiment demonstrated that the release of doxorubicin from drug‐loaded micelles was pH‐dependent. in vitro cytotoxic study showed that the introduction of phenylboronic acid resulted in lower IC50 against B16 cells than that in non‐modified F127‐chitosan micelles group, and the doxorubicin‐loaded micelles displayed lower in vitro activity against B16, A549, and HT‐29 cells than free doxorubicin did. However, in vivo experiments confirmed that the doxorubicin‐loaded micelles were safe for mouse main organs, obviously improved pharmacokinetic parameters of doxorubicin in rat and achieved comparable inhibition of tumor growth with no animal death in B16‐bearing mice models throughout the experiment when compared with free doxorubicin. The phenylboronic acid‐sialic acid interaction and pH‐sensitive drug release might play important roles in increased tumor targeting and therapeutic effect of the doxorubicin‐loaded micelles.
- 17 October 2019
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 11 (20) , 2647-2662
Linolenic Acid-Modified MPEG-PEI Micelles for Encapsulation of Amphotericin B
Aim: To encapsulate amphotericin B (AmB) with reduced toxicity and comparable activity. Results & methodology: The α-linolenic acid (ALA)-modified monomethoxy poly(ethylene glycol)-g-PEI-g-ALA conj...
- 17 October 2019
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 11 (20) , 2647-2662
Linolenic Acid-Modified MPEG-PEI Micelles for Encapsulation of Amphotericin B
Aim: To encapsulate amphotericin B (AmB) with reduced toxicity and comparable activity. Results & methodology: The α-linolenic acid (ALA)-modified monomethoxy poly(ethylene glycol)-g-PEI-g-ALA conj...
- 25 September 2018
- Published by Springer Nature in Journal of Nanoparticle Research
- Vol. 20 (10) , 261
Pluronic F127-cyclodextrin conjugate micelles for encapsulation of honokiol
- 25 September 2018
- Published by Springer Nature in Journal of Nanoparticle Research
- Vol. 20 (10) , 261
Pluronic F127-cyclodextrin conjugate micelles for encapsulation of honokiol
- 16 January 2015
- Published by Bentham Science Publishers Ltd. in Anti-Cancer Agents in Medicinal Chemistry
- Vol. 15 (2) , 176-188
Poly(ethylene glycol) amphiphilic copolymer for anticancer drugs delivery.
Abstract: Poly(ethylene glycol) is a water-soluble polymer. Due to its high safety and biocompatibility, it has been widely used to prepare amphiphilic copolymers for drug delivery. These copolymers can enhance water-solubility of hydrophobic drugs, improve their pharmacokinetic parameters and control their release from corresponding nanocarriers formed by its self-assembly. Anticancer drugs have some shortcomings such as lower water-solubility, bad targeting and some serious side-effects, which limit their applications and are dangerous to patients. So encapsulation of anticancer drugs into nanocarriers originated from its copolymeric derivates can improve their absorption, distribution, metabolism and excretion with better release properties and activities against cancer cells, increase their therapeutic effects, and realize their passive or active target delivery through structure modification. Recent research development of its drug delivery systems for anticancer drugs will be discussed.
- 16 January 2015
- Published by Bentham Science Publishers Ltd. in Anti-Cancer Agents in Medicinal Chemistry
- Vol. 15 (2) , 176-188
Poly(ethylene glycol) amphiphilic copolymer for anticancer drugs delivery.
Abstract: Poly(ethylene glycol) is a water-soluble polymer. Due to its high safety and biocompatibility, it has been widely used to prepare amphiphilic copolymers for drug delivery. These copolymers can enhance water-solubility of hydrophobic drugs, improve their pharmacokinetic parameters and control their release from corresponding nanocarriers formed by its self-assembly. Anticancer drugs have some shortcomings such as lower water-solubility, bad targeting and some serious side-effects, which limit their applications and are dangerous to patients. So encapsulation of anticancer drugs into nanocarriers originated from its copolymeric derivates can improve their absorption, distribution, metabolism and excretion with better release properties and activities against cancer cells, increase their therapeutic effects, and realize their passive or active target delivery through structure modification. Recent research development of its drug delivery systems for anticancer drugs will be discussed.
- 2 June 2013
- Published by Springer Nature in Journal of Nanoparticle Research
- Vol. 15 (6) , 1-12
Novel star-type methoxy-poly(ethylene glycol) (PEG)–poly(ε-caprolactone) (PCL) copolymeric nanoparticles for controlled release of curcumin
- 2 June 2013
- Published by Springer Nature in Journal of Nanoparticle Research
- Vol. 15 (6) , 1-12
Novel star-type methoxy-poly(ethylene glycol) (PEG)–poly(ε-caprolactone) (PCL) copolymeric nanoparticles for controlled release of curcumin